Showing 1 - 6 results of 6 for search 'Aruz Mesci', query time: 0.03s Refine Results
  1. 1
    Do We Have a Winner? Advocating for SBRT in HCC Management

    Do We Have a Winner? Advocating for SBRT in HCC Management by Amir H. Safavi, Laura A. Dawson, Aruz Mesci

    Published 2024-03-01
    Get full text
    Article
  2. 2
    RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer

    RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer by Aruz Mesci, Fabrice Lucien, Xiaoyong Huang, Eric H. Wang, David Shin, Michelle Meringer, Christianne Hoey, Jessica Ray, Paul C. Boutros, Hon S. Leong, Stanley K. Liu

    Published 2019-04-01
    Get full text
    Article
  3. 3
    18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer

    18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer by Aruz Mesci, Elham Ahmadi, Amr Ali, Mohammad Gouran-Savadkoohi, Evangelia Evelyn Tsakiridis, Olga-Demetra Biziotis, Tom Chow, Anil Kapoor, Monalisa Sur, Gregory R. Steinberg, Stanley Liu, Katherine Zukotynski, Theodoros Tsakiridis

    Published 2023-03-01
    Get full text
    Article
  4. 4
    Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

    Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses by Evangelia E. Tsakiridis, Lindsay Broadfield, Katarina Marcinko, Olga-Demetra Biziotis, Amr Ali, Bassem Mekhaeil, Elham Ahmadi, Kanwaldeep Singh, Aruz Mesci, Panayiotis G. Zacharidis, Alexander E. Anagnostopoulos, Tobias Berg, Paola Muti, Gregory R. Steinberg, Theodoros Tsakiridis

    Published 2021-11-01
    Get full text
    Article
  5. 5
    The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

    The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy by Amr Ali, Bassem Mekhaeil, Olga-Demetra Biziotis, Evangelia E. Tsakiridis, Elham Ahmadi, Jianhan Wu, Simon Wang, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Aruz Mesci, Stanley Liu, Tobias Berg, Jonathan L. Bramson, Gregory R. Steinberg, Theodoros Tsakiridis

    Published 2023-09-01
    Get full text
    Article
  6. 6
    Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

    Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α by Olga‐Demetra Biziotis, Evangelia Evelyn Tsakiridis, Amr Ali, Elham Ahmadi, Jianhan Wu, Simon Wang, Bassem Mekhaeil, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Bassam Abdulkarim, Ranjan K. Sur, Aruz Mesci, Peter Ellis, Tobias Berg, Jonathan L Bramson, Paola Muti, Gregory R Steinberg, Theodoros Tsakiridis

    Published 2023-11-01
    Get full text
    Article

Search Tools: